Mavengity — Healthcare & Medical https://mavengity.com/categories/healthcare-medical/ Health insurance, medical billing, and healthcare cost articles from Mavengity, explained in plain English. en-us Fri, 18 Sep 2026 19:32:30 +0000 https://mavengity.com/assets/img/mavengity-yt-logo.png Mavengity — Healthcare & Medical https://mavengity.com/categories/healthcare-medical/ California's New Rulebook Makes Private Equity Report Before It Can Buy Health Care https://mavengity.com/articles/healthcare-medical/california-ohca-ab1415-final-rules-pe-healthcare/ https://mavengity.com/articles/healthcare-medical/california-ohca-ab1415-final-rules-pe-healthcare/ Fri, 18 Sep 2026 00:00:00 +0000 healthcare-medical The final AB 1415 regulations set a 10 percent ownership trigger, keep governance rights on the hook, and put sale-leasebacks under review as the rules head to state approval. The Medicaid Drug Pricing Model Went National With Its Details Still Private https://mavengity.com/articles/healthcare-medical/medicaid-mfn-drug-pricing-national/ https://mavengity.com/articles/healthcare-medical/medicaid-mfn-drug-pricing-national/ Fri, 18 Sep 2026 00:00:00 +0000 healthcare-medical All 50 states, D.C., and Puerto Rico are joining the most-favored-nation model, while the deals that set the prices have never been published. A Small Japan Trial Gives the Hearing-Protection Drug a Second Opening https://mavengity.com/articles/healthcare-medical/pedmark-japan-trial-hearing-protection-cisplatin/ https://mavengity.com/articles/healthcare-medical/pedmark-japan-trial-hearing-protection-cisplatin/ Fri, 18 Sep 2026 00:00:00 +0000 healthcare-medical Fennec's investigator-led Phase 2 study met its endpoint with far less hearing loss than historical benchmarks, and the key finding is what did not happen to the chemo. A Childhood Leukemia Trial Just Replaced Chemotherapy Instead of Adding to It https://mavengity.com/articles/healthcare-medical/blinatumomab-replaces-chemotherapy-childhood-leukemia/ https://mavengity.com/articles/healthcare-medical/blinatumomab-replaces-chemotherapy-childhood-leukemia/ Thu, 17 Sep 2026 00:00:00 +0000 healthcare-medical A 709-child trial published in the New England Journal of Medicine found that swapping two chemotherapy blocks for the immunotherapy blinatumomab nearly halved relapses while cutting severe infections from 69 to 24 percent. Half of American Children Get Vaccines Through a Program That Cannot Order COVID Shots Yet https://mavengity.com/articles/healthcare-medical/cdc-children-covid-vaccine-orders-delayed/ https://mavengity.com/articles/healthcare-medical/cdc-children-covid-vaccine-orders-delayed/ Thu, 17 Sep 2026 00:00:00 +0000 healthcare-medical The CDC has not opened ordering for children's COVID-19 vaccines through the Vaccines for Children program, and states say the delay means low-income kids wait while commercial pharmacies already have the shots. A $20.5 Million Settlement Put a Price on Pharmacy Website Tracking https://mavengity.com/articles/healthcare-medical/cvs-criteo-20-million-settlement/ https://mavengity.com/articles/healthcare-medical/cvs-criteo-20-million-settlement/ Thu, 17 Sep 2026 00:00:00 +0000 healthcare-medical CVS and ad-tech firm Criteo settled a class action over web trackers that allegedly captured prescription searches, health conditions, and immunization data from CVS digital properties, with class members eligible for payments of up to $10. Dartmouth Health Is Cutting the Management Layer, Not the Bedside https://mavengity.com/articles/healthcare-medical/dartmouth-health-cuts-427-jobs/ https://mavengity.com/articles/healthcare-medical/dartmouth-health-cuts-427-jobs/ Thu, 17 Sep 2026 00:00:00 +0000 healthcare-medical New Hampshire's largest private employer will lay off 124 people and eliminate 303 open positions after a $63.5 million first-half loss, with the cuts concentrated in administration and leadership while clinical roles stay largely untouched. The First Treatment for Sanfilippo Syndrome Type A Arrived, and It Came as a Gene Therapy https://mavengity.com/articles/healthcare-medical/fayuvi-first-sanfilippo-a-gene-therapy/ https://mavengity.com/articles/healthcare-medical/fayuvi-first-sanfilippo-a-gene-therapy/ Thu, 17 Sep 2026 00:00:00 +0000 healthcare-medical The FDA approved Ultragenyx's Fayuvi, the first therapy for the fatal childhood disorder, on the strength of a single-arm trial compared against a natural history cohort, with the clearest benefit in children treated before regression. Testosterone Prescriptions for Women Nearly Tripled While the FDA Had No Approved Product. The Review Just Opened https://mavengity.com/articles/healthcare-medical/fda-testosterone-women-review-workshop/ https://mavengity.com/articles/healthcare-medical/fda-testosterone-women-review-workshop/ Thu, 17 Sep 2026 00:00:00 +0000 healthcare-medical The FDA held a public workshop on testosterone therapy for menopausal women as prescriptions surged 146 percent in three years, and the central question is what evidence would be enough for the first approved product. Novartis Halted Its ALS Drug After the Biomarkers Moved and the Patients Did Not https://mavengity.com/articles/healthcare-medical/novartis-halts-vhb937-als-trem2/ https://mavengity.com/articles/healthcare-medical/novartis-halts-vhb937-als-trem2/ Thu, 17 Sep 2026 00:00:00 +0000 healthcare-medical The Phase 2 ASTRALS trial of VHB937 missed both endpoints in 251 people with early ALS, ending the TREM2-targeting program and marking Novartis's fourth clinical setback in under a month. The Surgeon General Nominee Defended the MMR Vaccine, and the Senate Wanted More Than Belief https://mavengity.com/articles/healthcare-medical/saphier-vaccines-measles-senate-hearing/ https://mavengity.com/articles/healthcare-medical/saphier-vaccines-measles-senate-hearing/ Thu, 17 Sep 2026 00:00:00 +0000 healthcare-medical Dr. Nicole Saphier told the Senate health committee she believes the MMR vaccine is safe and does not cause autism, and the hearing became an argument about the difference between belief and established science, with a 731-case measles outbreak as the backdrop. Ivonescimab's Strongest Proof Is Half a World Away https://mavengity.com/articles/healthcare-medical/ivonescimab-harmoni-os-wclc-2026/ https://mavengity.com/articles/healthcare-medical/ivonescimab-harmoni-os-wclc-2026/ Wed, 16 Sep 2026 00:00:00 +0000 healthcare-medical Summit Therapeutics presented updated HARMONi overall survival data showing a 0.76 hazard ratio at WCLC 2026, while partner Akeso's China-only HARMONi-2 trial delivered a clean survival win against pembrolizumab, with an FDA decision due November 14. Medtronic Filled the Missing Piece in Its Robot Pitch https://mavengity.com/articles/healthcare-medical/medtronic-ligasure-hugo-clearance/ https://mavengity.com/articles/healthcare-medical/medtronic-ligasure-hugo-clearance/ Wed, 16 Sep 2026 00:00:00 +0000 healthcare-medical The FDA cleared Medtronic's LigaSure vessel-sealing instrument for the Hugo robotic surgery system, closing the biggest instrument gap in Hugo's US launch, though the robot's urology-only label still sets the ceiling on the near-term market. Trutakna's Confirmatory Trial Delivered the Number the Label Was Missing https://mavengity.com/articles/healthcare-medical/trutakna-origin-3-final-analysis-igan/ https://mavengity.com/articles/healthcare-medical/trutakna-origin-3-final-analysis-igan/ Wed, 16 Sep 2026 00:00:00 +0000 healthcare-medical Vera Therapeutics reported final ORIGIN 3 results showing TRUTAKNA cut the risk of a composite kidney disease progression endpoint by 76 percent in IgA nephropathy, the confirmatory data needed to convert its accelerated approval into a full one. The Canadian Pharmacy Option Closes for American Patients on October 22 https://mavengity.com/articles/healthcare-medical/canadian-prescription-import-ban-october-22/ https://mavengity.com/articles/healthcare-medical/canadian-prescription-import-ban-october-22/ Tue, 15 Sep 2026 00:00:00 +0000 healthcare-medical A U.S. Customs rule taking effect October 22 will block personal prescription shipments from Canadian and other foreign pharmacies, ending a decades-old pathway used by millions of Americans to afford medication. The Obesity Market Gets a Tolerability Play, and It Is Not a GLP-1 https://mavengity.com/articles/healthcare-medical/corbus-crb913-obesity-phase1b/ https://mavengity.com/articles/healthcare-medical/corbus-crb913-obesity-phase1b/ Tue, 15 Sep 2026 00:00:00 +0000 healthcare-medical Corbus Pharmaceuticals reported positive Phase 1b data for oral CRB-913, a CB1 inverse agonist that produced up to 5 percent weight loss in 12 weeks with a safety profile the company argues compares well against approved oral obesity drugs. A Psychedelic Drug Clears Its Third Phase 3 Trial, This Time for Anxiety https://mavengity.com/articles/healthcare-medical/definium-dt120-gad-panorama-phase3/ https://mavengity.com/articles/healthcare-medical/definium-dt120-gad-panorama-phase3/ Tue, 15 Sep 2026 00:00:00 +0000 healthcare-medical Definium Therapeutics reported positive topline results from the Panorama study of DT120, its LSD-derived oral treatment, with a placebo-adjusted 5.1-point improvement on the anxiety scale and an NDA filing planned for 2027. Phage Therapy Moves Toward the Mainstream With an FDA Breakthrough Nod https://mavengity.com/articles/healthcare-medical/fda-breakthrough-phage-therapy-staph/ https://mavengity.com/articles/healthcare-medical/fda-breakthrough-phage-therapy-staph/ Tue, 15 Sep 2026 00:00:00 +0000 healthcare-medical The FDA granted Breakthrough Therapy status to Armata's AP-SA02 phage cocktail for staph bloodstream infections, clearing a faster path to a Phase 3 trial and reviving a century-old approach to drug-resistant infections. In a Lung Cancer Where Survival Rarely Passes a Year, One Drug Nearly Doubled It https://mavengity.com/articles/healthcare-medical/gotistobart-squamous-nsclc-survival-data/ https://mavengity.com/articles/healthcare-medical/gotistobart-squamous-nsclc-survival-data/ Tue, 15 Sep 2026 00:00:00 +0000 healthcare-medical BioNTech and OncoC4's gotistobart produced median overall survival of 18.5 months versus 10.0 months for chemotherapy in previously treated squamous NSCLC, data presented at the World Conference on Lung Cancer. GSK Bets Up to $750 Million That a Preclinical Drug Can Fix Blood Cancer Therapy's Hardest Problem https://mavengity.com/articles/healthcare-medical/gsk-chimagen-multiple-myeloma-deal/ https://mavengity.com/articles/healthcare-medical/gsk-chimagen-multiple-myeloma-deal/ Tue, 15 Sep 2026 00:00:00 +0000 healthcare-medical GSK is acquiring global rights to a trispecific T cell engager from Shanghai's Chimagen Biosciences for multiple myeloma, a deal aimed at the tolerability problems that have kept powerful TCE drugs to late-line use.